Vivos Therapeutics (VVOS) Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Current Assets data on file, last reported at $4.8 million in Q1 2026.

• Quarterly Current Assets rose 33.6% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 33.6% YoY) and the FY2025 annual result came in at $4.4 million, down 41.34% from the prior year.
• Current Assets advanced to $4.8 million in Q1 2026 per VVOS's latest filing, from $4.4 million in the prior quarter.
• Across five years, Current Assets topped out at $21.6 million in Q1 2022 and bottomed at $2.0 million in Q3 2023.
• The 5-year median for Current Assets is $5.8 million (2025), against an average of $7.2 million.
• The widest annual swing landed in 2022, when Current Assets tumbled 80.15%; it then jumped 272.75% in 2024.
• Tracing VVOS's Current Assets over 5 years: stood at $5.4 million in 2022, then plunged by 54.63% to $2.5 million in 2023, then soared by 203.66% to $7.5 million in 2024, then plunged by 41.34% to $4.4 million in 2025, then climbed by 9.92% to $4.8 million in 2026.
• Per Business Quant, the three latest VVOS Current Assets figures stand at $4.8 million (Q1 2026), $4.4 million (Q4 2025), and $5.8 million (Q3 2025).

Peer Comparison